Nikang Therapeutics, Inc.
Clinical trials sponsored by Nikang Therapeutics, Inc., explained in plain language.
-
New pill tested for Tough-to-Treat kidney cancer
Disease control TerminatedThis study tested a new oral pill called NKT2152 for adults with advanced kidney cancer that had stopped responding to standard treatments. The first part aimed to find a safe and effective dose. The second part planned to see how well the pill could shrink tumors and control the…
Phase: PHASE1, PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New pill tested as potential lifeline for Tough-to-Treat cancers
Disease control TerminatedThis early-stage study tested a new oral drug called NKT3447 in adults with advanced solid tumors that had progressed despite standard treatments. The main goals were to find a safe dose and see how the body processes the drug. The study was later terminated and focused on specif…
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Terminated trial tests Last-Chance drugs for tough kidney cancers
Disease control TerminatedThis study tested two different drug combinations for people with advanced kidney cancer that had stopped responding to standard treatments. The trial aimed to find safe doses and see if these combinations could shrink tumors or slow disease progression. The study was terminated …
Phase: PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC